State Street’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-415,970
| Closed | -$19.9M | – | 4350 |
|
|
2025
Q3 | $19.9M | Sell |
415,970
-43,641
| -9% | -$1.21M | ﹤0.01% | 2251 |
|
|
2025
Q2 | $7.35M | Buy |
459,611
+10,450
| +2% | +$169K | ﹤0.01% | 2768 |
|
|
2025
Q1 | $6.83M | Sell |
449,161
-351,032
| -44% | -$5.63M | ﹤0.01% | 2744 |
|
|
2024
Q4 | $16.2M | Buy |
800,193
+388,213
| +94% | +$9.78M | ﹤0.01% | 2332 |
|
|
2024
Q3 | $10.6M | Buy |
411,980
+83,949
| +26% | +$1.4M | ﹤0.01% | 2564 |
|
|
2024
Q2 | $4.22M | Buy |
328,031
+294,288
| +872% | +$4.74M | ﹤0.01% | 2999 |
|
|
2024
Q1 | $773K | Buy |
+33,743
| New | +$1.19M | ﹤0.01% | 3534 |
|
|
2023
Q4 | – | Sell |
-6,545
| Closed | -$184K | – | 4489 |
|
|
2023
Q3 | $184K | Hold |
6,545
| – | – | ﹤0.01% | 3965 |
|
|
2023
Q2 | $199K | Sell |
6,545
-28,928
| -82% | -$739K | ﹤0.01% | 4013 |
|
|
2023
Q1 | $667K | Buy |
35,473
+1,809
| +5% | +$29.8K | ﹤0.01% | 3652 |
|
|
2022
Q4 | $343K | Buy |
33,664
+551
| +2% | +$8.85K | ﹤0.01% | 3901 |
|
|
2022
Q3 | $871K | Buy |
33,113
+233
| +0.7% | +$8.49K | ﹤0.01% | 3623 |
|
|
2022
Q2 | $1.48M | Buy |
32,880
+6,733
| +26% | +$531K | ﹤0.01% | 3551 |
|
|
2022
Q1 | $2.57M | Buy |
26,147
+7,547
| +41% | +$706K | ﹤0.01% | 3473 |
|
|
2021
Q4 | $2.84M | Buy |
18,600
+5,692
| +44% | +$842K | ﹤0.01% | 3515 |
|
|
2021
Q3 | $1.75M | Buy |
12,908
+3,412
| +36% | +$467K | ﹤0.01% | 3643 |
|
|
2021
Q2 | $1.4M | Buy |
+9,496
| New | +$1.45M | ﹤0.01% | 3607 |
|
State Street's TRML Position: Q4 2025 in Review
State Street sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 415,970 shares — an estimated $19.9M sold.
State Street first reported a position in TRML in Q2 2021 and held it in 17 quarters. The position peaked at $19.9M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- State Street reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- State Street sold 415,970 Tourmaline Bio shares in Q4 2025, an estimated $19.9M.
- State Street first reported a position in Tourmaline Bio in Q2 2021 and held it in 17 quarters.
- State Street's Tourmaline Bio position peaked at $19.9M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on State Street's 13F filing for Q4 2025, filed 13 Feb 2026.